The Pan-Canadian Tiered Pricing Framework and Chinese National Volume-Based Procurement: A Comparative Study Using Donabedian's Structure-Process-Outcome Framework

Author(s)

Wang Q1, Liu S2, Nie Z1, Zhu Z1, Fu Y3, Zhang J4, Wei X5, Wang T6, Yang L4
1Peking University, Beijing, China, 2Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China, 3Peking University, BEIJING, China, 4Peking University, Beijing, 11, China, 5London School of Hygiene & Tropical Medicine, London, UK, 6Shandong University, Jinan, China

Presentation Documents

OBJECTIVES:

Generic drugs have been deemed as a potentially powerful way to release financial burden on patients and health care systems. Tiered pricing framework and pooling purchasing power are two strategies, from the perspectives of manufacturer and buyers respectively, to achieve rational prices of generic drugs. We select pan-Canadian Tiered Pricing Framework (TPF) and Chinese National Volume-Based Procurement (NVBP) as comparators to explore the similarities and differences across the two policy implementation mechanisms and summarize the lessons for other jurisdictions.

METHODS:

Donabedian’s structure-process-outcome framework was applied for understanding two initiatives systematically.

RESULTS:

TPF is an upstream initiative aimed to lower the prices of generic drugs and to increase coverage and price consistency. NVBP is a downstream national initiative prioritized for drug price reduce. TPF process begins with application from manufacturer. By associate generic drug manufacturer number with price cut percentage, TPF leaves the choice to manufacturers to decide if join a specific generic drug market. Whereas, the Chinese government determine the NVBP list and holds authority to choose manufacturer(s) with lowest price(s). TPF provides clear drug price information to potential suppliers with unclear order quantity. The NVBP drug price is determined by tendering, while procurement volume is clear and massive. The effectiveness of TPF and NVBP is similar, 50% and 53% of price cut percentages, respectively. While the efficiency of TPF is 1.5 time as NVBP, with about 133 kinds of successfully-priced drugs per year. By comparing 60 drugs covered by both programs, the NVBP price is 57% of TPF counterpart averagely (1.1% ~ 301.6%), by purchase power parity. Under NVBP structure, single or more than 5 manufacturer(s) can achieve better results.

CONCLUSIONS:

Experience in the two countries shows coordinated pricing mechanism involves lots of piecemeal interactive problems, which a sophisticated system with a robust long-range plan may address better.

Conference/Value in Health Info

2023-05, ISPOR 2023, Boston, MA, USA

Value in Health, Volume 26, Issue 6, S2 (June 2023)

Code

HPR120

Topic

Economic Evaluation, Health Policy & Regulatory

Topic Subcategory

Cost-comparison, Effectiveness, Utility, Benefit Analysis, Pricing Policy & Schemes, Reimbursement & Access Policy

Disease

Drugs

Explore Related HEOR by Topic


Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×